AT1R/miR-26a通路在高血压血管重塑中的调控机制

张文倩; 王巧竹; 施佩菲; 冯雁京; 高登峰; 刘昕

doi:10.16016/j.1000-5404.201907236

您当前的位置：

首页 >

文章列表页 >

AT1R/miR-26a通路在高血压血管重塑中的调控机制

基础医学 | 更新时间：2026-01-09

- AT1R/miR-26a通路在高血压血管重塑中的调控机制
- Regulation mechanism of AT1R/miR-26a pathway in hypertensive vascular remodeling
- 第三军医大学学报 2020年42卷第1期页码：59-66
- 作者机构：
  
  710004 西安，西安交通大学第二附属医院心内科
- 作者简介：
- 基金信息：
  
  国家自然科学基金面上项目(81570382);国家自然科学基金面上项目(81872563)
- DOI：10.16016/j.1000-5404.201907236
  中图分类号： R544.1;R966;R977.6
- 收稿：2019-07-30，
  
  修回：2019-10-18，
  
  纸质出版：2020-01-15
- 稿件说明：
移动端阅览
张文倩, 王巧竹, 施佩菲, 等. AT1R/miR-26a通路在高血压血管重塑中的调控机制[J]. 第三军医大学学报, 2020,42(1):59-66.

Wenqian ZHANG, Qiaozhu WANG, Peifei SHI, et al. Regulation mechanism of AT1R/miR-26a pathway in hypertensive vascular remodeling[J]. Journal of Third Military Medical University, 2020, 42(1): 59-66.
张文倩, 王巧竹, 施佩菲, 等. AT1R/miR-26a通路在高血压血管重塑中的调控机制[J]. 第三军医大学学报, 2020,42(1):59-66. DOI： 10.16016/j.1000-5404.201907236.

Wenqian ZHANG, Qiaozhu WANG, Peifei SHI, et al. Regulation mechanism of AT1R/miR-26a pathway in hypertensive vascular remodeling[J]. Journal of Third Military Medical University, 2020, 42(1): 59-66. DOI： 10.16016/j.1000-5404.201907236.

摘要

目的

阐明AT1R/miR-26a通路在高血压血管重塑中的重要作用及分子机制。

方法

① 将24只8周龄雄性自发性高血压大鼠(SHRs)分为(

=8)：氯沙坦干预组[氯沙坦20 mg/(kg·d)灌胃

]

、哌唑嗪干预组[哌唑嗪5 mg/(kg·d)灌胃

]

、SHR模型对照组[纯水10 mL/(kg·d)灌胃

]

；雄性WKY大鼠作为正常对照组[纯水10 mL/(kg·d)灌胃

]

(

=6)，干预8周；干预前后3~5 d测定鼠尾动脉收缩压(SBP)，直至干预期满。②将各组大鼠麻醉取胸主动脉，qPCR检测大鼠胸主动脉miR-26a的表达水平。③剩余组织石蜡包埋行HE、Masson染色，α-actin和PCNA免疫组化染色。④Western blot检测大鼠胸主动脉AT1R、TGFβ1、p-smad3、CTGF表达情况。⑤将培养传至3~9代的大鼠胸主动脉平滑肌细胞(VSMC)分为AngⅡ处理组(VSMC+AngⅡ，AngⅡ10

-7

mol/L，作用24 h处理细胞)和对照组(VSMC+ Ctrl)(

=6)，qPCR检测miR-26a的表达水平，Western blot检测smad3和p-smad3表达情况。

结果

① 干预期满时，氯沙坦组、哌唑嗪组SBP明显低于模型对照组，但均高于正常对照组(

0.05)，氯沙坦组、哌唑嗪组间SBP差异无统计学意义(

0.05)。②氯沙坦组、哌唑嗪组胸主动脉miR-26a相对表达高于模型对照组(

0.05)，且氯沙坦组高于哌唑嗪组(

0.05)，但均较正常对照组表达低(

0.05)。③氯沙坦组、哌唑嗪组中膜厚度/管腔内经(MT/LD)、胶原体积分数(CVF)及平滑肌细胞增值指数均低于模型对照组(

0.05)，且氯沙坦组低于哌唑嗪组；正常对照组血管管壁未见明显增厚，平滑肌分布均匀且动脉内膜完整，无显著的胶原纤维沉积现象，平滑肌细胞排列整齐，胞核形态规则。④氯沙坦组、哌唑嗪组胸主动脉AT1R、p-smad3、TGFβ1、CTGF相对表达低于

模型对照组(

0.05)，且氯沙坦组低于哌唑嗪组(

0.05)，但均高于正常对照组(

0.05)。⑤VSMC+AngⅡ组细胞miR-26a表达显著低于对照组，且p-smad3表达显著高于VSMC+Ctrl组(

0.05)。

结论

miR-26a可阻止血压升高，且在高血压血管重塑进程中具有保护性作用；阻断AT1受体可通过上调miR-26a改善高血压血管重塑。

Abstract

Objective

To elucidate the important role and molecular mechanism of AT1R/miR-26a pathway in hypertensive vascular remodeling.

Methods

① Eight-week-old male spontaneously hypertensive rats (SHRs) were randomly divided into losartan group [gavage with losartan 20 mg/(kg·d) for 8 weeks

]

prazosin group [gavage with prazosin 5 mg/(kg·d) for 8 weeks

]

SHR control group [gavage with pure water 10 mL/(kg·d) for 8 weeks

]

with 8 animals in each groups. Six eight-week-old male WKY rats served as normal control group [gavage with pure water 10 mL/(kg·d) for 8 weeks

]

. All rats in each group were measured for systolic blood pressure (SBP) through tail artery in 3 to 5 d before and during the intervention period until the end of treatment. ② After the rats were anesthetized

the thoracic aorta were harvested for detecting the expression level of miR-26a by real-time quantitative polymerase chain reaction (qPCR). ③ The thoracic aorta was embedded in paraffin

and sectioned for HE and Masson staining

α-actin and PCNA immunohistochemistry. ④ The expression of AT1R

TGFβ1

p-smad3 and CTGF in the thoracic aorta were detected by Western blotting. ⑤ The rat thoracic aortic smooth muscle cells (VSMCs) at 3 to 9 passages were divided into AngⅡ treatment group (VSMCs+AngⅡ

AngⅡ10

-7

mol/L

treated for 24 h)

and control group (VSMC+Ctrl). qPCR was used to detect the expression level of miR-26a

and the expression of smad3 and p-smad3 was observed by Western blotting.

Results

① At the end of treatment received

SBP was significantly lower in the losartan an

d prazosin groups than the SHR control group

but all of them were obviously higher than that of normal control group (

0.05). There was no significant difference in SBP between the losartan and prazosin groups (

0.05). ②The expression of miR-26a in the thoracic aorta was notably higher in the losartan and prazosin groups than the SHR control group

but statistically lower than the normal control group (

0.05)

and that of the losartan group was higher than that of the prazosin group (

0.05). ③ Media thickness/lumen diameter (MT/LD)

collagen volume fraction (CVF)

and smooth muscle cell proliferation index in the losartan and prazosin groups were remarkably lower than those in the SHR control group (

0.05)

and those in the losartan group were lower than those of the prazosin group. The normal control group had no obvious thickening of the vascular wall

with well-arranged smooth muscle cells

and regular morphology of the nucleus

and no significant collagen fiber deposition. ④The expression levels of AT1R

p-smad3

TGFβ1 and CTGF in the thoracic aorta were significantly lower in the losartan and prazosin groups than the SHR control group (

0.05). Although those in the losartan group were lower than those of the prazosin group (

0.05)

the levels in the both group were higher than those of normal control group (

0.05). ⑤The expression of miR-26a was significantly lower

and that of p-smad3 was higher in VSMC+AngⅡ group when compared with VSMC+Ctrl group (

0.05).

Conclusion

miR-26a prevents blood pressure from rising and has a protective effect in the process of hypertensive vascular remodeling. Blocking AT1 receptor may improve the remodeling by up-regulating miR-26a.

关键词

Keywords

references

CAI G J, ZHANG X Y, WENG W J, et al . Associations between PPARG polymorphisms and the risk of essential hypertension[J ] . PLoS ONE, 2017, 12(7): e0181644. DOI:10.1371/journal.pone.0181644.

MULVANY M J. Small artery remodelling in hypertension[J]. Basic Clin Pharmacol Toxicol, 2012, 110(1): 49-55. DOI:10.1111/j.1742-7843.2011.00758.x.

LIU J, HUANG Y Q, CHEN S, et al . Role of endogenous sulfur dioxide in regulating vascular structural remodeling in hypertension[J ] . Oxid Med Cell Longev, 2016, 2016: 4529060. DOI:10.1155/2016/4529060.

WENZEL U, TURNER J E, KREBS C, et al . Immune mechanisms in arterial hypertension[J ] . J Am Soc Nephrol, 2016, 27(3): 677-686. DOI:10.1681/ASN.2015050562.

HAN Y C, LI H C. MiRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC)[J]. J Thorac Dis, 2018, 10(5): 3119-3131. DOI:10.21037/jtd.2018.05.32.

HOLMBERG J, BHATTACHARIYA A, ALAJBEGOVIC A, et al . Loss of vascular myogenic tone in miR-143/145 knockout mice is associated with hypertension-induced vascular lesions in small mesenteric arteries[J ] . Arterioscler Thromb Vasc Biol, 2018, 38(2): 414-424. DOI:10.1161/ATVBAHA.117.310499.

HAN W, HAN Y C, LIU X K, et al . Effect of miR-29a inhibition on ventricular hypertrophy induced by pressure overload[J ] . Cell Biochem Biophys, 2015, 71(2): 821-826. DOI:10.1007/s12013-014-0269-x.

YANG X Y, DONG M, WEN H, et al .MiR-26a contributes to the PDGF-BB-induced phenotypic switch of vascular smooth muscle cells by suppressing Smad1[J ] . Oncotarget, 2017, 8(44): 75844-75853. DOI:10.18632/oncotarget.17998.

LEEPER N J, RAIESDANA A, KOJIMA Y, et al . MicroRNA-26a is a novel regulator of vascular smooth muscle cell function[J ] . J Cell Physiol, 2011, 226(4): 1035-1043. DOI:10.1002/jcp.22422.

WU W, SHANG Y Q, DAI S L, et al . MiR-26a regulates vascular smooth muscle cell calcification in vitro through targeting CTGF[J ] . Bratisl Lek Listy, 2017, 118(8): 499-503. DOI:10.4149/BLL_2017_096.

张益珊, 袁苗, 黄园, 等. MiR-26a/b在AngⅡ导致的高血压血管重塑中的作用[J].西安交通大学学报(医学版), 2017, 38(5): 649-654. DOI:10.7652/jdyxb201705005.

ZHANG Y S, YUAN M, HUANG Y, et al . Role of miR-26a/b in AngⅡ-induced hypertensive vascular remodeling[J ] . J Xi'an Jiaotong Univ Med Sci, 2017, 38(5): 649-654. DOI:10.7652/jdyxb201705005.

HARVEY A, MONTEZANO A C, LOPES R A, et al . Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications[J ] . Can J Cardiol, 2016, 32(5): 659-668. DOI:10.1016/j.cjca.2016.02.070.

SAFAR M E, TOTO-MOUKOUO J J, BOUTHIER J A, et al . Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment[J ] . Circulation, 1987, 75(1 Pt 2): I156-I161.

JONES BUIE J N, GOODWIN A J, COOK J A, et al . The role of miRNAs in cardiovascular disease risk factors[J ] . Atherosclerosis, 2016, 254: 271-281. DOI:10.1016/j.atherosclerosis.2016.09.067.

MELMAN Y F, SHAH R, DANIELSON K, et al . Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: A translational pilot study[J ] . Circulation, 2015, 131(25): 2202-2216. DOI:10.1161/CIRCULATIONAHA.114.013220.

LI H S, GAO F, WANG X W, et al . Circulating microRNA-378 levels serve as a novel biomarker for assessing the severity of coronary stenosis in patients with coronary artery disease[J ] . Biosci Rep, 2019, 39(5): BSR20182016. DOI:10.1042/BSR20182016.

SHEN M C, MORTON J, DAVIDGE S T, et al . Loss of smooth muscle cell disintegrin and metalloproteinase 17 transiently suppresses angiotensin Ⅱ-induced hypertension and end-organ damage[J ] . J Mol Cell Cardiol, 2017, 103: 11-2 1. DOI:10.1016/j.yjmcc.2016.12.001.

LI R, XIAO J, QING X T, et al . Sp1 mediates a therapeutic role of MiR-7a/b in angiotensin Ⅱ-induced cardiac fibrosis via mechanism involving the TGF-β and MAPKs pathways in cardiac fibroblasts[J ] . PLoS ONE, 2015, 10(4): e0125513. DOI:10.1371/journal.pone.0125513..

LIANG H H, XU C Q, PAN Z W, et al . The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis[J ] . Mol Ther, 2014, 22(6): 1122-1133. DOI:10.1038/mt.2014.42.

LI A Y, WANG J J, YANG S C, et al . Protective role of Gentianella acuta on isoprenaline induced myocardial fibrosis in rats via inhibition of NF-κB pathway[J ] . Biomedecine Pharmacother, 2019, 110: 733-741. DOI:10.1016/j.biopha.2018.12.029.

SAKAI N, NAKAMURA M, LIPSON K E, et al . Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis[J ] . Sci Rep, 2017, 7(1): 5392. DOI:10.1038/s41598-017-05624-2.

AN E, PARK H, LEE A C. Inhibition of fibrotic contraction by C-phycocyanin through modulation of connective tissue growth factor and α-smooth muscle actin expression[J]. Tissue Eng Regen Med, 2016, 13(4): 388-395. DOI:10.1007/s13770-015-0104-5.

ZHANG Q H, HUANG F, YAO Y L, et al . Interaction of transforming growth factor-β-Smads/microRNA-362-3p/CD82 mediated by M2 macrophages promotes the process of epithelial-mesenchymal transition in hepatocellular carcinoma cells[J ] . Cancer Sci, 2019, 110(8): 2507-2519. DOI:10.1111/cas.14101.

ZHANG Y G, CHENG C T, WANG S, et al . Knockdown of FOXM1 inhibits activation of keloid fibroblasts and extracellular matrix production via inhibition of TGF-β1/Smad pathway[J ] . Life Sci, 2019, 232: 116637. DOI:10.1016/j.lfs.2019.116637.

CALVIER L, CHOUVARINE P, LEGCHENKO E, et al . PPARγ links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism[J ] . Cell Metab, 2017, 25(5): 1118-1134.e7. DOI:10.1016/j.cmet.2017.03.011.

GUAN T, ZHAO G Y, DUAN H H, et al . Activation of type 2 cannabinoid receptor (CB2R) by selective agonists regulates the deposition and remodelling of the extracellular matrix[J ] . Biomedecine Pharmacother, 2017, 95: 1704-1709. DOI:10.1016/j.biopha.2017.09.085.

POPOVIC N, BRIDENBAUGH E A, NEIGER J D, et al . Transforming growth factor-beta signaling in hypertensive remodeling of Porcine aorta[J ] . Am J Physiol Heart Circ Physiol, 2009, 297(6): H2044-H2053. DOI:10.1152/ajpheart.01015.2008.

TANG L H, PEI H F, YANG Y, et al . The inhibition of calpains ameliorates vascular restenosis through MMP2/TGF-β1 pathway[J ] . Sci Rep, 2016, 6: 29975. DOI:10.1038/srep29975.

LAN T H, HUANG X Q, TAN H M. Vascular fibrosis in atherosclerosis[J]. Cardiovasc Pathol, 2013, 22(5): 401-407. DOI:10.1016/j.carpath.2013.01.003.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于二维斑点追踪技术的纵向分层应变评价达格列净干预早期自发性高血压大鼠心肌功能变化

小动脉透明样变与IgA肾病合并高血压患者的临床病理特征相关性分析

住院高血压患者伴发轻度认知功能障碍的风险预测模型构建

TSPO调控肾脏血管紧张素Ⅱ1型受体表达促进原发性高血压大鼠血压升高

中国高血压患者并发脑卒中风险的Rothman-Keller模型研究